Boston Scientific Corporation (BSX)
| Market Cap | 58.99B |
| Revenue (ttm) | 11.47B |
| Net Income (ttm) | 1.10B |
| Shares Out | 1.42B |
| EPS (ttm) | 0.77 |
| PE Ratio | 53.84 |
| Forward PE | 21.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,355,045 |
| Open | 41.24 |
| Previous Close | 40.70 |
| Day's Range | 41.05 - 42.06 |
| 52-Week Range | 33.42 - 46.29 |
| Beta | 0.87 |
| Analysts | Strong Buy |
| Price Target | 51.20 (+23.7%) |
| Earnings Date | Oct 27, 2021 |
About BSX
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and r...
Financial Performance
Financial StatementsAnalyst Forecast
According to 27 analysts, the average rating for BSX stock is "Strong Buy." The 12-month stock price forecast is 51.20, which is an increase of 23.67% from the latest price.
News
Here's Why You Should Retain Boston Scientific (BSX) for Now
Investors are optimistic about Boston Scientific (BSX) owing to its solid third-quarter performance and impressive value-added acquisitions.
Boston Scientific Initiates Trial to Evaluate Industry's First Modular CRM System
MARLBOROUGH, Mass., Dec. 2, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) has initiated the MODULAR ATP clinical trial to evaluate the safety, performance and effectiveness of the mCRM™...
Boston Scientific Announces Upcoming Conference Schedule
MARLBOROUGH, Mass., Nov. 8, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in two upcoming investor conferences.
QIPT vs. BSX: Which Stock Should Value Investors Buy Now?
QIPT vs. BSX: Which Stock Is the Better Value Option?
4 Medical Products Stocks Poised to Beat This Earnings Season
Amid concerns surrounding growing COVID-19 cases affecting the medical products companies' legacy business, we are optimistic about IDXX, HSIC, CGC and PODD's results this time around.
Boston Scientific (BSX) Q3 Earnings Top Estimates, Margins Up
Barring CRM, Boston Scientific's (BSX) organic revenues at each of its core business segments and geographies increase in Q3.
Boston Scientific Q3 Earnings Comes Inline With Wall Street Expectations
Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.93 billion in Q3 of 2021, almost in line with the Wall Street estimate of $2.97 billion. Sales increased 10.3% Y/Y on a reported basis...
Boston Scientific (BSX) Q3 Earnings Beat Estimates
Boston Scientific (BSX) delivered earnings and revenue surprises of 2.50% and -1.61%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Boston Scientific Q3 Earnings
Boston Scientific (NYSE:BSX) reported its Q3 earnings results on Wednesday, October 27, 2021 at 06:30 AM. Here's what investors need to know about the announcement.
Boston Scientific Announces Results For Third Quarter 2021
MARLBOROUGH, Mass., Oct. 27, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $2.932 billion during the third quarter of 2021, growing 10.3 percent on a reported bas...
Medical Products Stock Q3 Earnings on Oct 27: TMO, EW & More
With the pandemic raging on, testing, vaccine and therapeutic makers witness huge market adoption of their COVID-related support products in Q3.
Boston Scientific (BSX) Product Launches to Drive Q3 Earnings
Within Urology/ Pelvic Health, Boston Scientific (BSX) is expected to have registered strong sales growth in Stone, Prostate Health and Pelvic Health franchises.
Boston Scientific (BSX) Reports Next Week: Wall Street Expects Earnings Growth
Boston Scientific (BSX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
3 Reasons to Hold on to Boston Scientific (BSX) Stock For Now
Investors are optimistic about Boston Scientific (BSX) given its recent acquisitions and strength in the structural heart business.
Boston Scientific (BSX) Inks New Deal to Buy Baylis Medical
The Baylis Medical buyout is expected to expand Boston Scientific's (BSX) electrophysiology and structural heart product offerings.
Boston Scientific's (BSX) Ranger DCB Trial Outcome Favorable
Boston Scientific's (BSX) Ranger DCB two-year data demonstrates a constant, high rate of efficacy in patients with more complex lesion subtypes.
Boston Scientific (BSX) Reports Data Backing Eluvia Stent
The positive data demonstrated the superiority of Boston Scientific's (BSX) Eluvia stent compared to bare metal stents in treating patients with peripheral artery disease.
Boston Scientific's Eluvia Drug-Eluting Vascular Stent Tops Bare Metal Stents
Boston Scientific Corporation (NYSE: BSX) has announced data for the Eluvia Drug-Eluting Vascular Stent System (Eluvia stent) at the Vascular InterVentional Advances meeting. Data presented included on...
Boston Scientific Eluvia™ Drug-Eluting Vascular Stent System Exhibits Superiority Compared to Bare Metal Stents
LAS VEGAS and MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Today, Boston Scientific Corporation (NYSE: BSX) announced positive data for the Eluvia™ Drug-Eluting Vascular Stent System (Eluvia stent) ...
Boston Scientific Beefs Up Electrophysiology, Structural Heart Portfolio With $1.75B Baylis Deal
Boston Scientific Corporation (NYSE: BSX) has agreed to acquire Baylis Medical Company Inc for an upfront payment of $1.75 billion. The acquisition will expand Boston Scientific's electrophysiology and ...
Boston Scientific Highlights Trial Data For EkoSonic System For Pulmonary Embolism
Boston Scientific Corporation (NYSE: BSX) announced results for the EkoSonic Endovascular System at the Vascular InterVentional Advances (VIVA) meeting. Related: Boston Scientific Acquires Provider O...
Boston Scientific Announces Agreement to Acquire Baylis Medical Company Inc.
MARLBOROUGH, Mass., Oct. 6, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that it has entered into a definitive agreement to acquire Baylis Medical Company Inc. for an u...
Positive Late-breaking Clinical Trial Data for the EkoSonic™ Endovascular System Presented at VIVA21
LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive results for the EkoSonic™ Endovascular System (EKOS system) during a late-breaking ...
Boston Scientific Announces Positive Late-Breaking Clinical Trial Data for the Ranger™ Drug-Coated Balloon
LAS VEGAS and MARLBOROUGH, Mass., Oct. 5, 2021 /PRNewswire/ -- Today, Boston Scientific (NYSE: BSX) announced positive results for the Ranger™ Drug-Coated Balloon (DCB) during a late-breaking clinical t...
Boston Scientific Announces Conference Call Discussing Third Quarter 2021 Results
MARLBOROUGH, Mass., Oct. 4, 2021 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter end...